Search - tctmd.com

Displaying 41 - 60 of 254

Sort: Relevancy | Date

News Conference News TCT 2023

More TRILUMINATE Patients Flesh Out Tricuspid TEER’s Impact

Yael L. Maxwell

October 24, 2023

Presentation TCT 2023

Revascularization For Patients With Left Ventricular Dysfunction: Are The Trials Still Relevant After a Decade of GDMT and Device Therapy?

Presenter: Clyde Yancy

October 24, 2023

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

News Conference News TCT 2023

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

Todd Neale

October 24, 2023

News Conference News TCT 2022

Pascal TEER Device Performs Well in Patients With Complex Anatomy

Yael L. Maxwell

September 26, 2022

News Conference News TCT 2022

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

L.A. McKeown

September 23, 2022

News Conference News TCT 2022

Newest MitraClip Iteration Performs Well in the Real World: EXPAND G4

Yael L. Maxwell

September 23, 2022

Presentation TCT 2022

State-of-the-Art Lecture: Future Device Therapies in PE

Presenter: Robert Lookstein

September 19, 2022

Presentation TCT 2022

Intermediate-Risk PE Case (NewYork-Presbyterian/Columbia University Irving Medical Center): Case Conclusion

Presenter: Sanjum Sethi

September 19, 2022

Presentation TCT 2022

What Do the Clinical Trials Tell Us to Do in Intermediate-Risk PE?

Presenter: Eric Secemsky

September 19, 2022

Presentation TCT 2022

Large Bore Thrombectomy: Are We Any Closer to Understanding Which Device Is Best?

Presenter: Catalin Toma

September 19, 2022

Presentation TCT 2022

CDT: New Devices, Drugs, and Duration?

Presenter: Andrew Sharp

September 19, 2022

Presentation TCT 2022

Intermediate-Risk PE Case (NewYork-Presbyterian/Columbia University Irving Medical Center): Case Intro

Presenter: Sanjum Sethi

September 19, 2022

News Conference News TCT 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Michael O'Riordan

September 19, 2022

News Conference News TCT 2022

RADIANCE II Confirms Ultrasound-Based Renal Denervation Lowers BP

Todd Neale

September 18, 2022

News Conference News TCT 2022

Pulmonary Artery Denervation in Idiopathic PAH Ups 6-Minute Walk Test

Shelley Wood

September 18, 2022

Presentation TCT 2022

Reducer Device Overview and Mechanism of Action

Presenter: Allen Jeremias

September 18, 2022

News Conference News TCT 2022

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

Todd Neale

September 18, 2022

News Conference News TCT 2022

As Time Goes By, Post-TAVI Thrombus Becomes More OAC Resistant

Michael O'Riordan

September 18, 2022

Presentation TCT 2022

Future Vision: Clinical and Technology Requirements for the Successful Development of Transcatheter Tricuspid Therapy Programs

Presenter: Azeem Latib

September 17, 2022

Advertisement

More TRILUMINATE Patients Flesh Out Tricuspid TEER’s Impact

Revascularization For Patients With Left Ventricular Dysfunction: Are The Trials Still Relevant After a Decade of GDMT and Device Therapy?

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

Pascal TEER Device Performs Well in Patients With Complex Anatomy

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

Newest MitraClip Iteration Performs Well in the Real World: EXPAND G4

State-of-the-Art Lecture: Future Device Therapies in PE

Intermediate-Risk PE Case (NewYork-Presbyterian/Columbia University Irving Medical Center): Case Conclusion

What Do the Clinical Trials Tell Us to Do in Intermediate-Risk PE?

Large Bore Thrombectomy: Are We Any Closer to Understanding Which Device Is Best?

CDT: New Devices, Drugs, and Duration?

Intermediate-Risk PE Case (NewYork-Presbyterian/Columbia University Irving Medical Center): Case Intro

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

RADIANCE II Confirms Ultrasound-Based Renal Denervation Lowers BP

Pulmonary Artery Denervation in Idiopathic PAH Ups 6-Minute Walk Test

Reducer Device Overview and Mechanism of Action

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

As Time Goes By, Post-TAVI Thrombus Becomes More OAC Resistant

Future Vision: Clinical and Technology Requirements for the Successful Development of Transcatheter Tricuspid Therapy Programs

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content